Mesa Laboratories INC /CO/ Schedule 13G passive stakes

Long Path Smaller Companies Fund, LP and affiliated entities report a beneficial ownership of 8.6% in Mesa Laboratories, Inc. following an amendment to their Schedule 13G filing.

Long Path Smaller Companies Fund, LP and affiliated entities report a beneficial ownership of 7.3% in Mesa Laboratories, Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Mesa Laboratories Inc. following an internal corporate realignment.

Long Path Smaller Companies Fund and its affiliates have reported a 5.6% beneficial ownership stake in Mesa Laboratories, Inc., totaling 311,703 shares.

The Vanguard Group has reported a 5.84% beneficial ownership stake in Mesa Laboratories Inc., holding 321,717 common shares as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership of Mesa Laboratories Inc.'s common stock as of September 30, 2025.

BlackRock, Inc. has reported a significant beneficial ownership stake of 14.4% in Mesa Laboratories Inc., holding 782,950 shares of common stock.

Royce & Associates LP has filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Mesa Laboratories, Inc. as of March 31, 2025.

Royce & Associates LP has filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.29% of Mesa Laboratories, Inc.'s common stock as of December 31, 2024.

Conestoga Capital Advisors and its affiliated funds have filed an updated Schedule 13G, revealing beneficial ownership of 11.38% and 7.62% respectively, in Mesa Laboratories Inc.'s common stock as of December 31, 2024.